BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 73
- Registration Number
- NCT04137120
- Locations
- 🇲🇽
Many locations, Multiple Locations, Mexico
Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed
- Conditions
- Interventions
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 193
- Registration Number
- NCT04132336
- Locations
- 🇺🇸
JBR Clinical Research, Salt Lake City, Utah, United States
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
- Conditions
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70
- Registration Number
- NCT04126733
- Locations
- 🇺🇸
Northwest Cancer Specialists, PC, Vancouver, Washington, United States
🇺🇸Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States
🇺🇸Baylor Charles A. Sammons Cancer Center at Dallas, Dallas, Texas, United States
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1
- Registration Number
- NCT04125693
- Locations
- 🇨🇭
Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 805
- Registration Number
- NCT04122976
- Locations
- 🇺🇸
Associated Urologists of NC, Raleigh, North Carolina, United States
🇺🇸Urology Centers of Alabama, Homewood, Alabama, United States
🇺🇸Research by Design, LLC, Chicago, Illinois, United States
Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3739
- Registration Number
- NCT04099238
- Locations
- 🇬🇧
Many facilities, Multiple Locations, United Kingdom
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 99999
- Registration Number
- NCT04097912
- Locations
- 🇬🇧
Many Locations, Multiple Locations, United Kingdom
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 56
- Registration Number
- NCT04095273
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Johns Hopkins Hospital/Health System, Baltimore, Maryland, United States
Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)
- Conditions
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 7
- Registration Number
- NCT04091386
- Locations
- 🇨🇳
Many Locations, Multiple Locations, Taiwan
🇺🇸Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders, Orange, California, United States
🇺🇸Tulane University, New Orleans, Louisiana, United States
Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT04085458
- Locations
- 🇪🇸
Ciutat Sanitaria i Universitaria de la Vall d'Hebron, Barcelona, Spain
🇪🇸Hospital Universitari i Politecnic La Fe | Hematologia, Valencia, Spain
🇪🇸Hospital Universitario "La Paz", Madrid, Spain